Darah focuses her practice on the representation of both underwriters and issuers on a variety of capital markets transactions. Darah also regularly counsels publicly traded companies on general corporate matters, including SEC reporting and corporate governance.
Immunology Company argenx Announces $1.27 Billion Global Offering
July 26, 2023
Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.
Prelude Therapeutics – $100 Million Follow-on Offering
May 18, 2023
Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.
Karuna Therapeutics – $862.5 Million Follow-on Offering
September 7, 2022
Cooley advised the underwriters in Karuna Therapeutics’ $862.5 million follow-on offering of 4,011,628 shares of common stock at a public offering price of $215 per share. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Partners Richard Segal, Jean Park, Div Gupta and associate Darah Protas led the Cooley team.
Verve Therapeutics – $258.8 Million Follow-on Offering
August 26, 2022
Cooley advised the underwriters in Verve Therapeutics’ $258.8 million follow-on offering of 9,583,334 shares of common stock at a public offering price of $27 per share. Verve is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene-editing medicines. Partners Rich Segal and Div Gupta, and associate Darah Protas, led the Cooley team.
